{"id":5540,"date":"2026-02-25T16:30:01","date_gmt":"2026-02-25T16:30:01","guid":{"rendered":"https:\/\/marketsfortress.com\/index.php\/2026\/02\/25\/gilead-to-acquire-arcellx-in-us7-8-billion-bet-on-cancer-therapy-2\/"},"modified":"2026-02-25T16:30:01","modified_gmt":"2026-02-25T16:30:01","slug":"gilead-to-acquire-arcellx-in-us7-8-billion-bet-on-cancer-therapy-2","status":"publish","type":"post","link":"https:\/\/marketsfortress.com\/index.php\/2026\/02\/25\/gilead-to-acquire-arcellx-in-us7-8-billion-bet-on-cancer-therapy-2\/","title":{"rendered":"Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy"},"content":{"rendered":"

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.<\/strong><\/p>\n

The agreement, publicized on Monday (February 23), will give Gilead full control of an experimental multiple myeloma treatment that the companies have been developing jointly. <\/p>\n

Gilead will pay US$115 per share in cash, plus a potential additional US$5 per share tied to future sales milestones. <\/p>\n

The therapy, known as anitocabtagene autoleucel, or anito-cel, is a next-generation CAR-T treatment targeting multiple myeloma, a blood cancer that often returns after several rounds of therapy. <\/p>\n<\/p>\n

So far, clinical trials suggest anito-cel can deliver lasting responses, with side effects the company says are more manageable than those seen with some current CAR-T therapies.<\/p>\n

The drug is currently under review by the US Food and Drug Administration (FDA) as a fourth-line treatment, with a decision expected by December 23, 2026. <\/p>\n

The filing is supported by results from a Phase 1 study and the pivotal Phase 2 iMMagine1 study.<\/p>\n

\u201cThis agreement reflects our conviction in the potential of anito-cel and our intention to move with speed so we can make the most of that potential for patients with multiple myeloma,\u201d said Daniel O\u2019Day, Chairman and CEO of Gilead. <\/p>\n

\u201cBeyond the potential launch this year, anito-cel could become a foundational treatment for multiple myeloma over time, including earlier lines of therapy,” the executive added. <\/p>\n

The deal also gives Gilead access to Arcellx\u2019s proprietary D-Domain platform, a technology designed to improve how engineered immune cells recognize cancer targets. <\/p>\n

Gilead said this could support future work in cell therapies, including potential in vivo approaches.<\/p>\n

The acquisition marks the company’s largest deal since 2020 and continues a strategy of using partnerships to secure promising oncology assets. The company has been looking to expand its cancer portfolio as sales of its COVID-19 treatment decline and long-term patent expirations approach in its core HIV franchise.<\/p>\n

Upon FDA approval of anito-cel, Gilead expects the deal to be accretive to earnings per share in 2028 and thereafter. <\/p>\n

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline. The agreement, publicized on Monday (February 23), will give Gilead full control of an <\/p>\n","protected":false},"author":0,"featured_media":5541,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[25],"tags":[],"class_list":{"0":"post-5540","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-investing"},"_links":{"self":[{"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/posts\/5540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/comments?post=5540"}],"version-history":[{"count":0,"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/posts\/5540\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/media\/5541"}],"wp:attachment":[{"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/media?parent=5540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/categories?post=5540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marketsfortress.com\/index.php\/wp-json\/wp\/v2\/tags?post=5540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}